Healthy Inc > Blog > Etoricoxib 90mg manufacturer India
Posted on:

Is etoricoxib safe in pregnancy?

In the pharmaceutical industry, Etoricoxib is a highly selective COX-2 inhibitor within the NSAID class. As a pharmacist and manufacturer, I must state clearly: Etoricoxib is generally contraindicated throughout pregnancy and is strictly prohibited in the third trimester.

At your WHO-GMP facility in Mumbai, where you likely produce the 60 mg, 90 mg, and 120 mg tablets, ensuring that your digital platforms and B2B dossiers reflect these safety mandates is a critical regulatory and ethical requirement.

Safety Profile by Trimester

Stage of PregnancySafety StatusTechnical Rationale
First TrimesterNot RecommendedLimited data exists, but NSAIDs are associated with an increased risk of miscarriage and congenital malformations (particularly cardiac septal defects) when taken early in gestation.
Second TrimesterAvoidMay be used only if the clinical benefit significantly outweighs the risk, under strict specialist supervision. Use after 20 weeks can cause fetal renal dysfunction leading to Oligohydramnios (low amniotic fluid).
Third TrimesterStrictly ForbiddenUse in the final trimester causes premature closure of the Ductus Arteriosus (a vital fetal heart vessel) and can lead to persistent pulmonary hypertension in the newborn.

Mechanism: Selective COX-2 Inhibition in Pregnancy

Etoricoxib is designed to target pain without the gastric side effects of older NSAIDs, but its mechanism is dangerous for a developing fetus:

Prostaglandin Blockade: Etoricoxib inhibits the enzyme Cyclooxygenase-2 (COX-2).

Fetal Circulation: Prostaglandins are essential for keeping the fetal ductus arteriosus open while the baby is in the womb. By blocking these, Etoricoxib can cause this vessel to close too early, leading to fetal heart failure.

Renal Impact: Prostaglandins also maintain blood flow to the fetal kidneys. Blockade reduces fetal urine production, which is the primary source of amniotic fluid.

The Pharmacist’s “Technical Warning”

  • The “Lactation” Caveat: It is currently unknown if Etoricoxib is excreted in human milk. Because of its long half-life (~22 hours), its use is generally not recommended while breastfeeding.

  • The “Fertility” Impact: Like all COX-2 inhibitors, Etoricoxib may delay or prevent ovulation. For B2B clients in the fertility space, it should be noted that the drug is not recommended for women attempting to conceive.

  • The “Paracetamol” Alternative: For your digital marketplace, you should position Paracetamol (Acetaminophen) as the standard first-line recommendation for pain management during pregnancy.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “Regulatory Compliance” USP: On your digital platform, ensure that the “Contraindications” section for Etoricoxib explicitly mentions pregnancy. This level of transparency builds trust with international Ministry of Health (MOH) auditors.

  • Stability for Export: Etoricoxib is stable but sensitive to moisture. Utilizing Alu-Alu blister packaging is the industry standard for ensuring a 36-month shelf life in Zone IVb tropical regions.

  • Dossier Support: We provide full CTD/eCTD Dossiers with comprehensive “Pregnancy and Lactation Labeling Rule” (PLLR) data to support your firm’s registration in international orthopedic and pain management tenders.

Etoricoxib Tablets

Posted on:

Is etoricoxib safe for kidneys?

In the pharmaceutical industry, Etoricoxib is a highly selective COX-2 inhibitor, a sub-class of non-steroidal anti-inflammatory drugs (NSAIDs). As a pharmacist and manufacturer, I view this molecule as “Renally Sensitive.” While it offers significant gastrointestinal protection compared to traditional NSAIDs, its effect on the kidneys is essentially identical to non-selective drugs like Ibuprofen or Diclofenac.

At your WHO-GMP facility in Mumbai, you likely manufacture this in 60 mg, 90 mg, and 120 mg strengths. For your B2B clients and digital platforms, the safety profile regarding the kidneys is determined by the patient’s baseline renal function.

Renal Safety Guidelines

Renal StatusSafety RecommendationTechnical Rationale
Normal FunctionGenerally SafeLow incidence of renal adverse events at standard therapeutic doses.
Mild/Moderate ImpairmentCaution (Max 60mg)No adjustment for CrCl $\ge$ 30 mL/min, but monitoring is advised.
Severe ImpairmentContraindicatedProhibited for patients with CrCl < 30 mL/min due to high risk of acute failure.

Mechanism: The Compensatory Prostaglandin Blockade

In a healthy body, the kidneys use prostaglandins to maintain blood flow. When a patient has compromised renal perfusion (due to dehydration, heart failure, or existing disease), Etoricoxib can disrupt this balance.

COX-2 Inhibition: Etoricoxib selectively targets the COX-2 enzyme in the kidney.

Prostaglandin Reduction: This inhibits the formation of vasodilating prostaglandins (like $PGI_2$ and $PGE_2$).

Renal Vasoconstriction: Without these prostaglandins, renal blood vessels constrict, leading to reduced blood flow (perfusion).

GFR Drop: The result can be a sudden decrease in the Glomerular Filtration Rate (GFR), leading to fluid retention, hypertension, and in severe cases, acute kidney injury.

The Pharmacist’s “Safety Check”

As you promote your firm online, providing these technical warnings is essential for professional authority:

  • Blood Pressure Monitoring: Etoricoxib is known to increase blood pressure (hypertension) in 3.4% to 4.7% of patients. This must be monitored closely, as high BP further strains the kidneys.

  • Electrolyte Imbalance: There is a risk of Hyperkalemia (high potassium), especially if the patient is also taking ACE inhibitors (like Enalapril) or ARBs (like Losartan).

  • Edema Warning: Advise B2B clients to watch for lower-extremity swelling (edema), which is a sign of sodium and water retention.

The Manufacturer’s Perspective: Technical & Export

From a production and B2B standpoint at your facility in Mumbai:

  • The “Shortest Duration” USP: On your multivendor marketplace, position Etoricoxib as a highly effective tool for acute pain (like gout or dental surgery) rather than chronic use. Long-term use significantly increases renal and cardiovascular risks.

  • Stability & Packaging: Etoricoxib is stable but should be protected from moisture to maintain its dissolution profile. We utilize Alu-Alu blister packaging to ensure a 36-month shelf life, vital for export to Zone IVb tropical regions.

  • Precision Manufacturing: Since renal sensitivity is dose-dependent, your Content Uniformity must be flawless. Highlighting your high-speed tablet press accuracy is a major USP for B2B buyers.

  • Dossier Support: We provide full CTD/eCTD Dossiers to support your firm’s registration in regulated markets worldwide.

Etoricoxib Tablets

Add to cart